Longeveron (LGVN) Non Operating Income (2022 - 2026)
Longeveron's (LGVN) quarterly Non Operating Income came in at $39000.0 in Q1 2026, down 77.06% year-on-year from $170000.0 in Q1 2025, and up 186.67% quarter-over-quarter from -$45000.0 in Q4 2025.
Longeveron (LGVN) Non Operating Income (2022 - 2026) Analysis & Trends
Longeveron's Non Operating Income history runs 5 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- On a quarterly basis, Non Operating Income fell 77.06% year-over-year to $39000.0 in Q1 2026; TTM through Mar 2026 was $452000.0, a 34.21% decrease from a year earlier, with the FY2025 full-year figure at $583000.0, up 6.19% from the prior year.
- Non Operating Income advanced to $39000.0 in Q1 2026 per LGVN's latest filing, from -$45000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $606000.0 in Q4 2022 and bottomed at -$1.4 million in Q2 2022.
- The 5-year median for Non Operating Income is $80000.0 (2023), against an average of -$333.33.
- Across the five-year window, Non Operating Income plunged 197.03% in 2023 and surged 431.25% in 2025, its largest moves.
- Year by year, Non Operating Income stood at $606000.0 in 2022, then plunged by 197.03% to -$588000.0 in 2023, then jumped by 134.01% to $200000.0 in 2024, then sank by 122.5% to -$45000.0 in 2025, then soared by 186.67% to $39000.0 in 2026.
- Per Business Quant, the three latest LGVN Non Operating Income figures stand at $39000.0 (Q1 2026), -$45000.0 (Q4 2025), and $89000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 39,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 369,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | -588,000.00 |
| Sep 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 606,000.00 |
| Jun 30, 2022 | -1.40 Mn |